New CKD treatment option approved in EU
The first SGLT2 inhibitor to demonstrate a statistically significant reduction…
The first SGLT2 inhibitor to demonstrate a statistically significant reduction in all-cause hospitalisations in chronic kidney disease (CKD) patients versus placebo has been approved in the EU.